Literature DB >> 15747683

Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors kit to produce platelet-rich plasma: a technical report.

Gernot Weibrich1, Wilfried K G Kleis, Walter E Hitzler, Gerd Hafner.   

Abstract

PURPOSE: The aim of this study was to compare a new method for the production of platelet-rich plasma (PRP), the plasma-rich-in-growth-factors kit (PRGF kit; G.A.C. Medicale San Antonio, Vitoria, Spain), with an established method, the Platelet Concentrate Collection System (PCCS; 3i/Implant Innovations, Palm Beach Gardens, FL) with respect to resulting cellular and growth factor contents.
MATERIALS AND METHODS: Whole blood was drawn from 51 healthy donors (20 men, 31 women) aged 19 to 59 years (mean +/- SD 35.12 +/- 9.65 years), and PRP was prepared by both methods.
RESULTS: Platelet counts differed significantly (signed rank test, P < .001 for all) between the donor blood (274,200 +/- 54,050/microL), the PCCS PRP preparation (1,641,800 +/- 426,820/microL), and the PRGF kit PRP preparation (513,630 +/- 139,470/microL). The PCCS concentrated leukocytes (whole blood, 6,992 +/- 2,011/microL; PCCS PRP, 14,153 +/- 7,577/microL), while the PRGF kit produced a leukocyte-poor PRP (65 +/- 108/microL). Higher concentrations of transforming growth factor beta1 (TGF-beta1) and platelet-derived growth factor AB (PDGF-AB) were found in the PCCS PRP (TGF-/beta1, 290 +/- 95 ng/mL; PDGF-AB, 157 +/- 62 ng/mL) than in the Anitua PRGF kit PRP (TGF-beta1, 73 +/- 26 ng/mL; PDGF-AB, 47 +/- 21 ng/mL). Statistical analysis showed significant differences (P < .001 for TGF-beta1 and P < .01 for PDGF-AB). DISCUSSION: The results of this study and some data in the literature indicate that the content of growth factors in PRP can vary tremendously, depending on the system used for the preparation of PRP.
CONCLUSION: PCCS collects more platelets and leukocytes than the PRGF kit. This results in significantly higher growth factor levels. Further in vivo studies are needed to determine whether this results in a clinically different biologic effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15747683

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Implants        ISSN: 0882-2786            Impact factor:   2.804


  37 in total

1.  Human AB serum for generation of mesenchymal stem cells from human chorionic villi: comparison with other source and other media including platelet lysate.

Authors:  A Poloni; G Maurizi; F Serrani; S Mancini; G Discepoli; A L Tranquilli; R Bencivenga; P Leoni
Journal:  Cell Prolif       Date:  2011-12-14       Impact factor: 6.831

Review 2.  Platelet-rich plasma for the replenishment of bone.

Authors:  Jameel Iqbal; Samuel H Pepkowitz; Ellen Klapper
Journal:  Curr Osteoporos Rep       Date:  2011-12       Impact factor: 5.096

3.  Uncultured marrow mononuclear cells delivered within fibrin glue hydrogels to porous scaffolds enhance bone regeneration within critical-sized rat cranial defects.

Authors:  James D Kretlow; Patrick P Spicer; John A Jansen; Charles A Vacanti; F Kurtis Kasper; Antonios G Mikos
Journal:  Tissue Eng Part A       Date:  2010-10-12       Impact factor: 3.845

4.  Quantitative and qualitative analysis of platelet-rich plasma collection using the Haemonetics Cell Saver 5 in open heart surgery.

Authors:  David W Fried; Joseph J Leo; Frederick P Weber; Mansoor Husain; James Cullen
Journal:  J Extra Corpor Technol       Date:  2006-09

5.  Reflections about the optimisation of the treatment of tendinopathies with PRP.

Authors:  Jean-François Kaux; Marc Bouvard; Christelle Lecut; Cécile Oury; André Gothot; Mikel Sanchez; Jean-Michel Crielaard
Journal:  Muscles Ligaments Tendons J       Date:  2015-03-27

6.  Determining the Effect of Preparation and Storage: An Effort to Streamline Platelet Components as a Source of Growth Factors for Clinical Application.

Authors:  Atul Sonker; Anju Dubey
Journal:  Transfus Med Hemother       Date:  2015-01-29       Impact factor: 3.747

7.  Merchants shall be expelled from the Temple: the PRGF(®) (Plasma-Preparation Rich in Growth Factors)-Endoret(®) case.

Authors:  David M Dohan Ehrenfest; Chang-Qing Zhang; Nelson R Pinto; Tomasz Bielecki
Journal:  Muscles Ligaments Tendons J       Date:  2015-02-05

Review 8.  Platelet Derived Biomaterials for Therapeutic Use: Review of Technical Aspects.

Authors:  Satyam Arora; Naveen Agnihotri
Journal:  Indian J Hematol Blood Transfus       Date:  2016-03-29       Impact factor: 0.900

Review 9.  The use of platelet-rich plasma to augment conservative and surgical treatment of hip and pelvic disorders.

Authors:  Matthew J Kraeutler; Tigran Garabekyan; Omer Mei-Dan
Journal:  Muscles Ligaments Tendons J       Date:  2016-12-21

10.  Effectiveness of two methods for preparation of autologous platelet-rich plasma: an experimental study in rabbits.

Authors:  Maria J H Nagata; Michel R Messora; Flávia A C Furlaneto; Stephen E Fucini; Alvaro F Bosco; Valdir G Garcia; Tatiana M Deliberador; Luiz G N de Melo
Journal:  Eur J Dent       Date:  2010-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.